A minimally invasive outpatient procedure may help people avoid regaining weight after stopping popular medications like Ozempic and semaglutide, according to research being presented at Digestive Disease Week® (DDW) 2026. About 70% of people who stop these drugs eventually regain much of the weight they lost, often within 18 months. Nearly one in five adults with obesity has used a glucagon-like peptide-1 (GLP-1), highlighting the scale of this challenge. Researchers report the first blinded, randomized, sham-controlled evidence that a procedure called duodenal mucosal resurfacing may offer a safe and lasting way to maintain weight loss without ongoing medication. The findings suggest it could help patients hold onto the benefits they achieved while taking drugs such as Ozempic or other GLP-1 therapies.…